CHEK2 and breast carcinoma: Indeed, the NCCN has proposed high-risk surveillance including MRI in ATM and CHEK2 mutation carriers, which represent the majority of mutations identified by the panel in predisposing genes other than BRCA. Other authors have warned about the risk of disinformation and the implementation of inappropriate risk-management strategies in cases with limited cancer risk management guidelines, as such guidelines are not sufficiently developed to allow accurate targeted genetic counseling and breast cancer risk management [27].